High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
FY2026Q3
18.05M
-4.62%
0.080
+700%
21.46M
-4.36%
0.207
+37.78%
21.44M
+5.31%
0.203
-106.07%
Estimates Revision
The market is revising Upward the revenue expectations for Simulations Plus, Inc. (SLP) for FY2025, with the revenue forecasts being adjusted by 1.18% over the past three months. During the same period, the stock price has changed by 48.05%.
Revenue Estimates for FY2025
Revise Upward
+1.18%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-1.7%
In Past 3 Month
Stock Price
Go Up
+48.05%
In Past 3 Month
4 Analyst Rating
Wall Street analysts forecast SLP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLP is 16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 20.490
Low
16.00
Averages
16.00
High
16.00
Current: 20.490
Low
16.00
Averages
16.00
High
16.00
TD Cowen
TD Cowen
Hold
initiated
$16
2025-09-30
Reason
TD Cowen
TD Cowen
Price Target
$16
2025-09-30
initiated
Hold
Reason
TD Cowen initiated coverage of Simulations Plus with a Hold rating and $16 price target. The firm says the company's software and services biosimulation platform drives significant cost and time savings for its biopharma customers. TD is "constructive" on the outlook for Simulations' software revenue growth, but says a customer spending slowdown in the company's consulting services "looms large" while synergies from its restructuring initiatives will take time.
KeyBanc
Overweight -> Sector Weight
downgrade
2025-07-15
Reason
KeyBanc
Price Target
2025-07-15
downgrade
Overweight -> Sector Weight
Reason
KeyBanc last night downgraded Simulations Plus to Sector Weight from Overweight without a price target. The company's fiscal Q3 results and forward outlook highlighted the ongoing challenged biopharma end market environment, the analyst tells investors in a research note. The firm believes the challenges will impact Simulations Plus "more sharply" given its customer concentration and biotech exposure. KeyBanc sees weaker customer demand continuing in the near-to-middle-term with no recovery in the biotech end market.
Stephens
Stephens
Overweight
downgrade
$28 -> $20
2025-07-15
Reason
Stephens
Stephens
Price Target
$28 -> $20
2025-07-15
downgrade
Overweight
Reason
Stephens lowered the firm's price target on Simulations Plus to $20 from $28 and keeps an Overweight rating on the shares. Simulations Plus reported slightly better than expected quarterly results, though adjusted EBITDA guidance was slightly lower than the firm modeled, the analyst says. The fourth quarter outlook represents conservatism rather than a further slide in fundamentals, and Stephens sees limited downside from here.
Craig-Hallum
Buy
downgrade
$36 -> $31
2025-07-15
Reason
Craig-Hallum
Price Target
$36 -> $31
2025-07-15
downgrade
Buy
Reason
Craig-Hallum lowered the firm's price target on Simulations Plus to $31 from $36 and keeps a Buy rating on the shares. The firm notes the company reported final Q3 results with revenues slightly ahead of the pre-release range and revenue guidance for FY25 reaffirmed. Craig-Hallum believes that the headwinds the company is facing will be relatively short-term in nature and given the recent regulatory guidance which calls for more use of AI/simulation in the discovery and development of pharmaceuticals, the firm thinks Simulations Plus will return to double-digit revenue growth and adjusted EBITDA margins of 30%-plus.
KeyBanc
Overweight -> Sector Weight
downgrade
2025-07-14
Reason
KeyBanc
Price Target
2025-07-14
downgrade
Overweight -> Sector Weight
Reason
KeyBanc downgraded Simulations Plus to Sector Weight from Overweight.
BTIG
Buy
downgrade
$41 -> $25
2025-07-07
Reason
BTIG
Price Target
$41 -> $25
2025-07-07
downgrade
Buy
Reason
BTIG lowered the firm's price target on Simulations Plus to $25 from $41 and keeps a Buy rating on the shares following the firm's survey of biopharma manufacturers. R&D Services budgets will likely face the most risk and headwinds over the next 2 years, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Simulations Plus Inc (SLP.O) is 38.22, compared to its 5-year average forward P/E of 71.58. For a more detailed relative valuation and DCF analysis to assess Simulations Plus Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Undervalued
5Y Average PE
71.58
Current PE
38.22
Overvalued PE
94.37
Undervalued PE
48.79
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
34.15
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
49.44
Undervalued EV/EBITDA
18.86
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
13.31
Current PS
0.00
Overvalued PS
19.53
Undervalued PS
7.08
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 2417.79% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 2417.79% over the last month.
Sold
Bought
SLP News & Events
Events Timeline
(ET)
2025-12-02
10:50:00
FDA Proposes Guidance for Streamlined Safety Assessments of Monospecific Antibodies
2025-12-01 (ET)
2025-12-01
16:10:00
Simulations Plus Reports Q4 Revenue of $17.5M, Exceeding Consensus
2025-12-01
16:10:00
FY26 Revenue Expected at $79M-$82M, In Line with Consensus
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/a5acaf3015e73cac2fc9e6d1a794b15740b81ba7570938be1328d761ec5ec5e7.jpg)
Preview
9.5
12-03NASDAQ.COMPinnedReasons Behind the Surge in Simulations Plus Stock Today
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/6e612afb363dca4cbacbdd5fa8819b6122f63a12727ef87025cc50e9614ba970.png)
Preview
9.5
12-03BenzingaPinnedSimulations Plus Shares Rise Due to Strong Earnings and Biotech Market Recovery
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/128d0de4c2967db6d2ad04e89ef0b20b28bbd49b675e46ebcf6f2f7ccbfdea9d.jpg)
Preview
9.5
12-02NASDAQ.COMPinnedSimulations Plus Reports Decline in Q4 Revenue; Confirms FY26 Forecast; Shares Fall
Sign Up For More News
People Also Watch
FAQ
What is Simulations Plus Inc (SLP) stock price today?
What is Simulations Plus Inc (SLP)'s business?
What is the price predicton of SLP Stock?
What is Simulations Plus Inc (SLP)'s revenue for the last quarter?
What is Simulations Plus Inc (SLP)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Simulations Plus Inc (SLP)'s fundamentals?
How many employees does Simulations Plus Inc (SLP). have?